In order to uncover the therapeutic mechanism of theabrownin in treating NASH, we measured the levels of FGF21 mRNA and protein, as well as the phosphorylation of p38 in the liver. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.